AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Eleven Biotherapeutics Announces Additional Financing of $20 Million

November 25, 2014

 Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

November 19, 2014

 - Phase 2 study met primary objective of showing anti-tumor activity as measured by overall response rate at Q3W dosing schedule -

- Promising anti-tumor activity and survival in patients with KRAS mutant tumors and squamous histology -

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

November 18, 2014

 -Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -

-Data Support Initiation of Multiple Expansion Cohorts in the First Half of 2015-

Black Duck Software Appoints Global Sales Veteran Adam Clay as Vice President of Worldwide Sales

Black Duck Software Appoints Global Sales Veteran Adam Clay as Vice President of Worldwide Sales

November 18, 2014

Black Duck Software, the leading OSS Logistics solutions provider enabling the deployment and management of open source software (OSS), today announced the appointment of Adam Clay as Vice President of Worldwide Sales.

Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer

Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer

November 17, 2014

CAMBRIDGE, Mass., Nov. 17, 2014 /PRNewswire/ -- Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.

Joule Names Industry Veteran Serge Tchuruk as President and CEO

Joule Names Industry Veteran Serge Tchuruk as President and CEO

November 13, 2014

Tchuruk will lead the organization in its transition towards commercialization

Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome

Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome

November 13, 2014

Symbiota Appoints Dr. Robert Berendes as Executive Chairman

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

November 13, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.